Amgen price target lowered to $230 from $240 at Barclays

Barclays analyst Carter Gould lowered the firm’s price target on Amgen to $230 from $240 and keeps an Underweight rating on the shares post the Q4 results. The company’s outlook for the base business in 2023 "is not overly encouraging," the analyst tells investors in a research note. The firm expects the focus on Tepezza growth dynamics will soon dominate the discussion for Amgen.